Michael Roth has served as Vice President of Quality at Nurix since May 2024.  Mr. Roth has over 30 years of pharmaceutical experience overseeing all aspects of quality assurance and compliance, as well as extensive experience managing PAI/BIMO inspections and commercial activities. Prior to joining Nurix, Mr. Roth served as Vice President of Quality Assurance at Rain Oncology, where he managed the quality groups and supported the company’s clinical and non-clinical studies.  Previously, he served as Vice President of Quality Assurance at Principia Biopharma, Executive Director of Quality Assurance at Rigel Pharmaceuticals, and Director of Quality Control and Assurance at Zosano Pharma. He has collaborated on three drugs that received FDA approval. Mr. Roth holds a B.A. in Chemistry from the State University College of Buffalo and an M.A. in Pharmacology from the State University of New York at Buffalo (RPMI). 

Marine Champsaur, Ph.D., has served as Vice President and Head of Medical Affairs since August 2022. Prior to joining Nurix, Dr. Champsaur provided scientific strategy and communications consulting services to early-stage biotech companies across a range of treatment modalities spanning the autoimmune and inflammatory disease, vaccine, and oncology space. Before that, Dr. Champsaur played a pivotal role in building the medical affairs function at Dermira, Inc., where she led the medical strategy and communications team. Early in her career, she held roles of increasing responsibility at UCB Pharma within immunology global medical affairs. Dr. Champsaur holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and a Ph.D. in Immunology from the University of California, San Francisco.

Linda L. Neuman, M.D., M.B.A., has served as Vice President of Clinical Development at Nurix since May 2024.  Dr. Neuman is trained as an internist, practiced medicine for 10 years prior to entering industry, and has more than 12 years of drug development experience in both oncology and rare disease. Prior to joining Nurix, she held senior positions in clinical development at Aeglea BioTherapeutics, Catalyst Biosciences, Adverum Biotechnologies, Sunesis Pharmaceuticals, Puma Biotechnology, and Onyx Pharmaceuticals.  Dr. Neuman completed her internal medicine residency at St. Vincent’s Hospital in Indianapolis.  She holds a B.S. in Biology from Southern Illinois University at Edwardsville, an M.B.A from Indiana Wesleyan University, and an M.D from Southern Illinois University.

Joseph D. Robinson has served as Vice President, Facilities Operations at Nurix since July 2023. Mr. Robinson has been responsible for developing the facilities, real estate, lab services and operations functions at Nurix since he joined the company in January 2016. Prior to Nurix, Mr. Robinson served in positions of increasing responsibility developing and growing administrative and operational functions for early-stage companies, including Presidio Pharmaceuticals, a developer of anti-viral therapeutics, and VaxGen, a vaccine company. Mr. Robinson began his career at the Conant Medical Group. Mr. Robinson studied Communications at San Francisco State University and Management at St. Mary’s College of California.  

Eva Kras, M.S., joined Nurix in 2023 and has served as Vice President and Head of Regulatory Affairs since February 2024. Ms. Kras has over 22 years of experience in drug development, spanning early to late-stage programs across several therapeutic areas, including oncology/hematology and rare disease. Throughout her career, she has been responsible for developing innovative regulatory strategies leading to numerous global regulatory marketing approvals. Prior to joining Nurix, she held a variety of roles at Amgen, Seattle Genetics, BioMarin, GSK, Coherus and most recently BeiGene. Ms. Kras earned her B.S. in Pharmacology from the University of California, Santa Barbara, and her M.S. in Regulatory Science from the USC School of Pharmacy.

Eren Demirhan, Ph.D., has served as Vice President and Head of Biometrics at Nurix since March 2021, leading the Company’s Biostatistics and Clinical Data Science efforts. Dr. Demirhan brings over 17 years of experience in drug pharmaceuticals and biotechnology, championing data-driven drug development ideology and implementation. Prior to joining Nurix, Dr. Demirhan served in a variety of roles at Allogene Therapeutics, Medivation, Onyx Pharmaceuticals, Novartis, Biogen, and GSK. Dr. Demirhan holds a B.A. in Statistics from Middle East Technical University, a Ph.D. in Statistics from North Carolina State University and an M.B.A from Kenan Flagler Business School, University of North Carolina – Chapel Hill.

Elizabeth Bosch, Ph.D., has served as Vice President, Alliance and Program Management at Nurix since January 2023 and served as the company’s Head of Alliance Management and Research Program Management from June 2018 through December 2022. Prior to joining Nurix, she worked at Five Prime Therapeutics, Inc., Incyte Corporation and Sentinel Biosciences, Inc. Dr. Bosch earned an M.S. and Ph.D. from the University of California, Los Angeles and completed her postdoctoral work at the Cell Signaling Dept, DNAX/Schering Plough Biopharma and the Jules Stein Eye Institute at UCLA. 

Bev Benson, Ph.D., has served as Vice President and Head of Clinical Science at Nurix since January 2022. Dr. Benson has over 22 years of experience in drug development across numerous indications and has worked on five drugs that have received FDA approval. During her career, she has worked as a Clinical Scientist serving in positions of increasing responsibility at Amgen, Jazz Pharmaceuticals, BeiGene, CytomX Therapeutics and most recently at Principia Biopharma. Dr. Benson holds a B.S. in Microbiology from the University of Oklahoma and a Ph.D. in Pharmacology & Toxicology from the University of Kansas, and she completed her postdoctoral fellowship at the Huntsman Cancer Institute at the University of Utah.

Frederick Cohen, Ph.D., joined Nurix in 2017 and has served as Head of Medicinal Chemistry since April 2020. He has more than 20 years of experience in small molecule drug discovery, spanning multiple therapeutic areas including oncology, neurodegeneration and antibiotics. Prior to joining Nurix, he served at Achaogen, Genentech, and Tularik. Dr. Cohen earned his B.A. in Chemistry from Occidental College and his Ph.D. in Chemistry from the University of California, Irvine.

Christopher B. Phelps, Ph.D., has served as Vice President and Head of Early Discovery at Nurix since January 2021. Dr. Phelps has more than 10 years of experience in small molecule discovery, with a focus on DNA encoded library technology. Prior to joining Nurix, he served in multiple roles at GSK, most recently as Director of DNA Encoded Library Screening. He earned his B.S. in Biology from St. Lawrence University and his Ph.D. in Chemistry and Biochemistry from the University of California, San Diego, and he completed his post-doctoral training at Harvard University.